EuroPCR 2024 | Influence and Effect of CAD Physiopathological Patterns in the Safety and Efficacy of PCI

Coronary revascularization aims at improving coronary flow. However, after successful percutaneous coronary intervention (PCI) a significant number of patients might experience suboptimal coronary physiology. It has been observed that low fractional flow reserve (FFR) after PCI is associated to poor prognosis. Also, improved FFR after procedure directly correlates with improved angina symptoms. 

EuroPCR 2024

Pullback pressure during PCI can identify different CAD patterns. Studies have suggested that PCI might be more effective in focal coronary artery lesions defined by their physiology. Pullback pressure gradient (PPG) is used to standardize these patterns by classifying them into diffuse patterns (PPG=0.28), combined coronary artery disease (PPG=0.45) and focal PPG (PPG=0.86).

The main goal of this study was to assess PPG to predict FFR post PCI and analyze its impact on procedural outcomes. A single arm multicenter study was carried out including stable patients with positive FFR programed for treatment. The study excluded patients with bifurcation lesions, severe coronary artery tortuosity, aorto-ostial coronary lesions and recent MI.

In total, 993 patients were included, mean age 67.7, and 76% men. 89% presented stable angina. It was found that post PCI FFR was significantly higher in patients with focal CAD vs. patients with diffuse disease (0.89 vs 0.84 respectively, p<0.001). The area under the curve was 0.82 (CI95% 0.79-0.84).

Read also: EuroPCR 2024 | OBSERVANT II: TAVR in the “Real World”.

Focal CAD was associated with lower incidence of target vessel failure, cardiac death and MI. Also PPG prior intervention predicted post PCI FFR. Periprocedural MI were less frequent in patients with focal CAD. 

In conclusion, the authors suggest PPG can have additional clinical value to FFR in decision making when treating CAD. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Carlos Collet at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....